Questions? Call 1-855-454-6369 or email
Monday to Friday from 9:00 AM to 7:00 PM ET
For patients with diabetic macular edema, macular edema following branch or central retinal vein occlusion, and noninfectious posterior segment uveitis

Welcome to the OZURDEX® Savings Program


Our savings program can help patients pay
as little as $50* for OZURDEX®.
Find out if you are eligible below. *Maximum benefit per treatment is $1000 per eye.
How does the program work?
Patients:
1
Please click the green "Enroll and Get Member ID” button BEFORE receiving OZURDEX®
  • Insurance information, personal identification, and contact information are needed
  • Patient's household income must meet the following requirements
  • Income limits by household size
    1
    $60,000
    2-4
    $125,000
    5+
    $150,000
Practices may assist in patient enrollment
Note: If selected, enrolling via our paper application process will incur additional processing time.
2
Print member ID number and give it to your healthcare provider’s office.
Eligible patients are immediately provided a member ID number online to print and use for OZURDEX® injections for 1 year from issue date.*
Practices:
1
Collect patient member ID.
2
Determine patient’s out-of-pocket cost.
3
Please click the blue "Apply for Reimbursement" button to submit reimbursement request. Enter the patient's Member ID number and healthcare provider’s contact information into the enrollment form. Please upload the following supporting documents:
  • HCFA/CMS 1500 form
  • Patient's Explanation of Benefits document(s)
  • Purchase Charge Documentation (Patient's Invoice for OZURDEX® Treatment) or signed Physician Attestation Form. Please note you may also use the electronic attestation by checking the box on the reimbursement page.
Templates and examples of these required documents can be found here. The physician office can also fax these documents to 1-347-630-0347.
4
Receive a check from Truveris.
Who is eligible?

Patients must meet the following criteria to be eligible:

  • Be a resident of the United States (or its territories) and is at least 18 years of age
  • Be prescribed OZURDEX® according to its approved FDA labeling
  • Receive treatment during or after December 2017
  • Have commercial or private health insurance
  • Have insurance coverage for OZURDEX® for an approved use
  • Have no government-sponsored insurance coverage
  • Patient's household income meets the following requirements
  • Income limits by household size
    1
    $60,000
    2-4
    $125,000
    5+
    $150,000

Patients are not eligible if they have government insurance (eg, prescriptions are paid in part or full by any state or federally funded programs, including but not limited to Medicare, Medicaid, Medigap, Veterans Affairs [VA], Department of Defense [DoD], CHAMPVA, or TRICARE).

When should patients enroll?

Patients should enroll before visiting their physician.


For Patients, Caregivers
and Physician Offices
For Physician Offices
Check Your Eligibility
I am at least 18 years of age.
I currently live in the United States, Puerto Rico, or Guam.
I have private/commercial health insurance. (eg, through my employer or an
exchange, NOT a federal or state health program such as Medicare, Medicaid, TRICARE, or similar program.)
My current income meets the following requirements*:
  • For a household size of 1, less than or equal to $60,000
  • For a household size of 2-4, less than or equal to $125,000
  • For a household size of 5 or more, less than or equal to $150,000
I received or will receive treatment with OZURDEX® (dexamethasone intravitreal
implant) during or after December 2017.
* Household = tax filer + spouse + number of tax dependents. Follow these basic rules when including members of your household: (1) include your spouse if you’re legally married; (2) if you plan to claim someone as a tax dependent, do include them on your application; (3) if you won’t claim someone as a tax dependent, don’t include them.
Approved Uses

OZURDEX® (dexamethasone intravitreal implant) is a prescription medicine that is an implant injected into the eye (vitreous) and used:

  • To treat adults with diabetic macular edema
  • To treat adults with swelling of the macula (macular edema) following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
  • To treat adults with noninfectious inflammation of the uvea (uveitis) affecting the back segment of the eye
IMPORTANT SAFETY INFORMATION
When Not to Use OZURDEX®

OZURDEX® should not be used if you have any infections in or around the eyes, including most viral diseases of the cornea and conjunctiva, including active herpes viral infection of the eye, vaccinia, varicella, mycobacterial infections, and fungal diseases.

OZURDEX® should not be used if you have glaucoma that has progressed to a cup-to-disc ratio of greater than 0.8.

OZURDEX® should not be used if you have a posterior lens capsule that is torn or ruptured.

OZURDEX® should not be used if you are allergic to any of its ingredients.

Warnings and Precautions

Injections into the vitreous in the eye, including those with OZURDEX®, are associated with serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, and retinal detachments. Your eye doctor should monitor you regularly after the injection.

Use of corticosteroids including OZURDEX® may produce posterior subcapsular cataracts, increased eye pressure, glaucoma, and may increase the establishment of secondary eye infections due to bacteria, fungi, or viruses. Let your doctor know if you have a history of ocular herpes simplex as corticosteroids are not recommended in these patients.

Common Side Effects in Diabetic Macular Edema

The most common side effects reported in patients with diabetic macular edema include: cataract, increased eye pressure, conjunctival blood spot, reduced vision, inflammation of the conjunctiva, specks that float in the field of vision, swelling of the conjunctiva, dry eye, vitreous detachment, vitreous opacities, retinal aneurysm, foreign body sensation, corneal erosion, inflammation of the cornea, anterior chamber inflammation, retinal tear, drooping eyelid, high blood pressure, and bronchitis.

Common Side Effects in Retinal Vein Occlusion and Noninfectious Posterior Segment Uveitis

The most common side effects reported in patients for retinal vein occlusion and uveitis include: increased eye pressure, conjunctival blood spot, eye pain, eye redness, ocular hypertension, cataract, vitreous detachment, and headache.

Patient Counseling Information

After repeated injections with OZURDEX®, a cataract may occur. If this occurs, your vision will decrease and you will need an operation to remove the cataract and restore your vision. You may develop increased eye pressure with OZURDEX® that will need to be managed with eye drops, and rarely, with surgery.

In the days following injection with OZURDEX®, you may be at risk for potential complications including in particular, but not limited to, the development of serious eye infection or increased eye pressure. If your eye becomes red, sensitive to light, painful, or develops a change in vision, you should seek immediate care from your eye doctor. You may experience temporary visual blurring after receiving an injection and should not drive or use machinery until your vision has resolved.

Please click here for full Prescribing Information.